At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Nov 6, 2026 at 09:57 ET
Halozyme announced that Johnson & Johnson received FDA accelerated approval for RYBREVANT FASPRO (amivantamab co-formulated with Halozyme's ENHANZE technology) for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after prior chemo and anti-PD-(L)1 therapy. This is the first approval of a dual-targeted therapy in this setting and expands the commercial reach of Halozyme's ENHANZE platform beyond lung cancer.
- FDA accelerated approval for RYBREVANT FASPRO (amivantamab + hyaluronidase-lpuj) in recurrent/metastatic HNSCC after platinum chemo and anti-PD-(L)1 failure
- First dual-targeted therapy (EGFR/MET) approved in this setting
- Co-formulated with Halozyme's ENHANZE drug delivery technology
- Approval expands ENHANZE's commercial reach beyond lung cancer into a new indication with high unmet need
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access